Aerpio Pharmaceuticals(AADI) - 2024 Q3 - Quarterly Results

Sales Performance - FYARRO® sales reached $7.2 million in Q3 2024, reflecting a 21% year-over-year growth[1] - The net product sales of FYARRO increased by 17% from Q2 2024, driven by strong demand and a nearly 90% reorder rate[2] - Total revenue for the quarter ended September 30, 2024, was$ 7.2 million, resulting solely from FYARRO sales[5] Financial Position - Cash, cash equivalents, and short-term investments as of September 30, 2024, were $62.6 million, down from$ 108.8 million as of December 31, 2023[5] - Operating expenses for Q3 2024 were $20.6 million, a decrease from$ 23.8 million in the prior year quarter[6] - The net loss for Q3 2024 was $12.5 million, compared to a net loss of$ 16.3 million for the same period in 2023[6] - Aadi expects to fund operations into at least the second half of 2026 based on current plans[8] Strategic Initiatives - Aadi is conducting a comprehensive strategic review to maximize shareholder value, with no specific timeline provided for completion[4] - The Phase 2 trials of nab-sirolimus for advanced endometrial cancer and neuroendocrine tumors have enrolled 24 and 12 patients, respectively[4] - The company has transitioned patients from the halted PRECISION1 trial to an expanded access protocol, with a report expected in 2025[3]